CK5/6, EGFR, Ki-67, cyclin D1, and nm23-H1 protein expressions as predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients

Medical Oncology

Volumn 28, Issue SUPPL. 1, 2011, Pages

  Li, Xi Ru ^a   Liu, Mei ^a   Zhang, Yan Jun ^a   Wang, Jian Dong ^a   Zheng, Yi Qiong ^a   Li, Jie ^a   Ma, Bing ^a   Song, Xin ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Basal like; Locally advanced breast cancer; Neoadjuvant chemotherapy; nm23 H1; Triple negative breast cancers

Indexed keywords

CYCLIN D1; CYTOKERATIN 5; CYTOKERATIN 6; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; KI 67 ANTIGEN; NUCLEOSIDE DIPHOSPHATE KINASE A; PROGESTERONE RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER;

EID: 84655174988     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9742-6     Document Type: Article

References (31)

1. J Lee YH Im SH Lee 2008 Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer Cancer Chemother Pharmacol 61 569 577
2. B Fisher A Brown E Mamounas 1997 Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18 J Clin Oncol 15 2483 2493 (Pubitemid 27289876)
3. P Rastogi SJ Anderson HD Bear 2008 Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 J Clin Oncol 26 778 785 (Pubitemid 351264391)
4. HM Kuerer LA Newman TL Smith 1999 Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy J Clin Oncol 17 460 469 (Pubitemid 29075229)
5. AU Buzdar NK Ibrahim D Francis 2005 Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer J Clin Oncol 23 3676 3685
6. V Guarneri K Broglio SW Kau 2006 Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors J Clin Oncol 24 1037 1044 (Pubitemid 46638799)
7. JS Jeruss EA Mittendorf SL Tucker 2008 Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy J Clin Oncol 26 246 252
8. G von Minckwitz M Rezai S Loibl 2010 Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study J Clin Oncol 28 2015 2023
9. A Robidoux AU Buzdar E Quinaux 2010 A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer Clin Breast Cancer 10 81 86
10. R Dent M Trudeau KI Pritchard 2007 Triplenegative breast cancer: clinical features and patterns of recurrence Clin Cancer Res 13 4429 4434 (Pubitemid 47219710)
11. KR Bauer M Brown RD Cress 2007 Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry Cancer 109 1721 1728 (Pubitemid 46668532)
12. LA Carey EC Dees L Sawyer 2007 The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes Clin Cancer Res 13 2329 2334 (Pubitemid 46698581)
13. BG Haffty Q Yang M Reiss 2006 Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer J Clin Oncol 24 5652 5657 (Pubitemid 46631305)
14. C Liedtke C Mazouni KR Hess 2008 Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer J Clin Oncol 26 1275 1281
15. H Nogi T Kobayashi M Suzuki 2009 EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer Oncol Rep 21 413 417
16. Masuda H, Masuda N, Kodama Y et al. Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patients. Cancer Chemother Pharmacol. 2010 [Epub ahead of print].
17. A Goldhirsch JH Glick RD Gelber 2001 Meeting highlights: international consensus panel on the treatment of primary breast cancer. Seventh international conference on adjuvant therapy of primary breast cancer J Clin Oncol 19 3817 3827 (Pubitemid 32880060)
18. A Di Leo D Larsimont D Gancberg 2001 HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide Ann Oncol 12 1081 1089 (Pubitemid 32834488)
19. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687 1717
20. EH Romond EA Perez J Bryant 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 1673 1684 (Pubitemid 41464706)
21. I Smith M Procter RD Gelber 2007 2-year followup of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial Lancet 369 29 36 (Pubitemid 46039831)
22. O Dizdar K Altundag 2010 Current and emerging treatment options in triple-negative breast cancer Oncol Rev 4 5 13
23. B Fisher J Bryant N Wolmark 1998 Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 2672 2685 (Pubitemid 28363030)
24. JA van der Hage CJ van de Velde JP Julien 2001 Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902 J Clin Oncol 19 4224 4237
25. R Rouzier CM Perou WF Symmans 2005 Breast cancer molecular subtypes respond differently to preoperative chemotherapy Clin Cancer Res 11 5678 5685 (Pubitemid 41170290)
26. CQ Zhu W Shih CH Ling 2006 Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation J Clin Pathol 59 790 800 (Pubitemid 44211740)
27. NH Au M Cheang DG Huntsman 2004 Evaluation of immunohistochemical markers in nonsmall cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers J Pathol 204 101 109 (Pubitemid 39214487)
28. CR Berney RJ Fisher J Yang 1999 Protein markers in colorectal cancer: predictors of liver metastasis Ann Surg 230 179 184 (Pubitemid 30191883)
29. N Iizuka K Hirose T Noma 1999 The nm23-H1 gene as a predictor of sensitivity to chemotherapeutic agents in oesophageal squamous cell carcinoma Br J Cancer 81 469 475 (Pubitemid 29458801)
30. G Scambia G Ferrandina M Marone 1996 nm23 in ovarian cancer: correlation with clinical outcome and other clinicopathologic and biochemical prognostic parameters J Clin Oncol 14 334 342 (Pubitemid 26053263)
31. N Iizuka K Miyamoto A Tangoku 2000 Downregulation of intracellular nm23-H1 prevents cisplatin-induced DNA damage in oesophageal cancer cells: possible association with Na(+), K(+)-ATPase Br J Cancer 83 1209 1215